Introduction
B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the Western hemisphere, is still considered to be incurable. 1, 2 The typical course of the disease is characterized by the accumulation of monoclonal CD5/CD19/CD23-positive resting B cells, exhibiting a defect in initiating apoptosis. 3 A prominent feature of B-CLL cells is the overexpression of the transmembrane glycoprotein CD23, which is transcribed from two different promoters giving rise to two isoforms, CD23a and CD23b. CD23a has been implicated in the antiapoptotic state of B-CLL lymphocytes. 4 We have recently shown that Notch2 is involved in the upregulation of CD23a expression in B-CLL cells. 5 Notch2 belongs to a family of short-range signaling transmembrane receptors, which participate in many binary cell fate decisions by modulating differentiation, proliferation, and apoptosis in response to extracellular stimuli. 6 After activation, the intracellular domain of Notch receptors (NotchIC) translocates to the nucleus where it activates CBF1 responsive genes. [7] [8] [9] Constitutive activation of Notch signaling contributes to the pathogenesis of leukemias and lymphomas. Overexpression of truncated, constitutively active forms of Notch1 and Notch2 resembling NotchIC, for instance, contribute to the formation of T-cell leukemias in mice and humans. [10] [11] [12] More recently, evidence for a direct role of Notch2 in the generation of murine B-cell subsets has been provided. Notch2 is the family member preferentially expressed in mature B cells, 13 and plays a determining role for the development of B1 and marginal zone B cells. 14, 15 Importantly, activation of Notch proteins has been demonstrated to inhibit apoptosis in different cellular contexts. [16] [17] [18] [19] [20] Notch1 expression provides significant protection to thymocytes and T-cell lines from glucocorticoid and TCRmediated apoptosis, respectively. 16, 17 Protective function for Notch1 has further been described for murine erythroleukemia cells by controlling the apoptotic threshold during differentiation and growth. 19 However, a direct antiapoptotic function for Notch2 in human B cells has not been demonstrated so far.
The activity of NotchIC is strictly controlled not only by Notch-modulating proteins but also by the rapid turnover through proteasome-or lysosome-mediated degradation. [21] [22] [23] [24] The ubiquitin-proteasome pathway is the major extra-lysosomal machinery for protein degradation and is involved in the regulation of cell growth, apoptosis, and gene expression. 25, 26 Proteins are specifically targeted for destruction by the 26S proteasome through the addition of polyubiquitin chains consisting of at least four ubiquitin polypeptides.
Inhibition of proteasome by specific proteasome inhibitors (PI) such as lactacystin has been shown to induce apoptosis in various leukemias and other malignancies. 27, 28 These compounds very efficiently induce apoptosis also in tumor cells that are resistant to conventional chemotherapy. Remarkably, B-CLL cells are about 10 times more sensitive to lactacystin-induced apoptosis than normal peripheral B lymphocytes. 29 Bortezomib, another potent proteasome inhibitor, has entered clinical evaluation for treatment of B-CLL. 30, 31 The molecular mechanisms underlying the PI-induced apoptosis in B-CLL cells, however, remain unclear.
In this study, we investigated the effects of PI on the activity of Notch2 in B-CLL cells. PI treatment led to inhibition of nuclear Notch2IC activity and downregulation of CD23. These effects were selective and were observed early in the process of apoptosis. Furthermore, the influence of Notch2IC activity on the sensitivity to PI-induced apoptosis was examined in Notch2IC-transduced B-cell lines. Taken together, the results suggest that downregulation of the transcriptional activity of this factor may be required for the full apoptotic response to proteasome inhibitors.
Materials and methods

Drugs and cell culture
Bortezomib (VELCADE s , formerly PS-341, Millennium Pharmaceuticals, Boston, MA, USA) or MG132 (Sigma, St Louis, MO, USA) were dissolved in DMSO at 10 mM, and for all incubations control samples were prepared containing equal amounts of DMSO. Inhibitors for caspase 3 (CPP32/Apopain) and g-secretase (compound E) were purchased from Calbiochem (La Jolla, CA, USA). Peripheral blood mononuclear cells from B-CLL patients (B-CLL cells) were isolated using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) centrifugation. Lymphoid cells were cultured in complete RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all reagents were obtained from Gibco, Life Technologies Inc., Paisley, UK) in a humidified atmosphere containing 5% CO 2 at 371C. Drug incubations were carried out in complete tissue culture medium. BL41, a CD23
À human Burkitt's lymphoma cell line (DSMZ, Braunschweig, Germany), was cultured in complete RPMI 1640 medium.
Flow cytometry
Flow cytometry was performed on a FACScan s using CellQuest Pro s software (Becton Dickinson, San Jose, CA, USA). Annexin V and propidium iodide staining was performed to estimate the percentage of cells undergoing apoptosis using a kit from Alexis Biochemicals (Montreal, Canada), according to the supplier's instructions. Directly conjugated monoclonal antibodies to CD23 and CD5 were from Becton Dickinson, San Jose, CA, USA. For the comparison of mean fluorescence intensities, the instrument settings for fluorescence and compensation were the same for all experiments. Surface staining for CD23 reveals total expression of both isoforms.
Preparation of nuclear extracts and EMSA
Preparation of nuclear extracts and EMSA were carried out exactly as described. 5 An oligonucleotide derived from the CD23a promoter (specific for the CD23a isoform) containing a CBF1-binding site (5 0 -CTCTAGTTCTCACCCAATTC-3 0 ) was annealed with the respective reverse complementary strand and used in the binding reactions. For analysis of NF-AT binding, an oligonucleotide with the sequence 5 0 -CGCCCAAAGAA-GAAAATTTGTTTCATA-3 0 was used. 32 For antibody inhibition assays of Notch2IC, the Notch2IC (C651.6DbHN) antibody (obtained from the Developmental Studies Hybridoma Bank, developed at the University of Iowa, Department of Biological Science, Iowa City, IA 52242, USA) was incubated with nuclear extracts for 30 min at 41C prior to addition of probe DNA.
Transduction of BL41
A Notch2IC 'gain-of-function' phenotype was created in BL41, a CD23 À human Burkitt's lymphoma cell line. Shortly, the packaging cell line pT67 was transfected with pLXIN vector (Clontech Laboratories, Palo Alto, CA, USA) containing cDNA sequences coding for the intracytoplasmic portion of human Notch2IC (amino acids # 1684-2471) or Notch2ICdP (amino acids #1684-2382), a fragment lacking the protein destabilizing PEST region. After 24 and 48 h, cell culture supernatants were collected and used to infect BL41 cells in logarithmic growth phase. Infection was carried out for 6 h in the presence of 6 mg/ ml Polybrene (Sigma, St Louis, MO, USA). Cell culture supernatants from pT67 cells transfected with empty pLXIN vector served as negative controls. At 2 days after transduction, G418 selection was started at a concentration of 500 mg/ml and continued for 3 weeks until transduced cells started to grow. Successful integration of the transduced sequences was controlled by PCR amplification of Notch2 fragments using primers specific for the newly introduced fragments.
Reverse transcription (RT)-PCR
Total RNA was extracted using the TRIzol isolation system (Invitrogen/Life Technologies, Paisley, UK), according to the manufacturer's instructions. RT-PCR reactions were performed on total RNA (50 ng per reaction) using primer sequences as follows: CD23a, forward 5 0 -ATGGAGGAAGGTCAATATTCA-3 0 and reverse 5 0 -GCATCATCACGCAGTCCTCGC-3 0 (29 cycles, specific for the CD23a isoform); Notch2, forward 5 0 -CTGGATG CAGGTGCAGATGCCAATGC-3 0 and reverse 5 0 -GCAGAAGT CAACACGGTGCCTGGAGG-3 0 (27 cycles). The amount of bactin was simultaneously quantified for normalization of templates using the following primers: b-actin, forward 5 0 -GTGGGAATTCGTCAGAAGGACTCCTATGTG-3 0 and reverse 5 0 -GAAGTCTAGAGCAACATAGCACAGCTTCTC-3 0 (25 cycles).
Results
PI inhibitors induce apoptosis in B-CLL cells and reduce surface expression of CD23
Freshly isolated B-CLL cells (n ¼ 35) were incubated with various concentrations of PI for 24 h and the effect on cell viability was evaluated by flow-cytometric analysis. Two proteasome inhibitors, bortezomib, already tested in clinical trials for several malignancies, 33, 34 and MG-132 were investigated. As shown in Figure 1a , treatment with bortezomib induced apoptosis in all samples, but to different degrees. This is in accordance with published data. 35 After 24 h incubation at a PI concentration of 10 nM, the percentage of cells in an early (Annexin V þ ) or late stage (Annexin V þ /propidium iodide þ ) of apoptosis was found to be in the range between 10 and 95% ( Figure 1a) . In parallel to cell viability, the surface expression of CD23 decreased in all B-CLL cultures from a mean level of 75% in controls to 31% in the drug-treated samples ( Figure 1b ). To get further insight into the kinetics of PI-mediated cell death, B-CLL cells from two patients, one with faster and one with slower response to PI, were studied (Figure 1c and d) . After 24 h with 100 nM bortezomib in both cases, only a small percentage (o10%) of the cells survived. However, in case 1, the response rate after the first 6 h of incubation was 50% of apoptotic cells (Figure 1c ), while in case 2 only 20% were in apoptosis (Figure 1d) .
At the same time, the exposure to PI led to a reduction of CD23 surface expression in the viable cell populations ( Figure  1c and d) . To test for the specificity of this effect, CD5, another surface marker of the leukemic cells, was determined. As seen in Figure 1c and d, CD5 expression remained unchanged during the whole period of incubation, indicating that inhibition of the proteasome did not affect all surface molecules.
Relative sensitivity to PI correlates with CD23 mean fluorescence intensity
To investigate possible correlations between the sensitivity of B-CLL cells to PI-mediated apoptosis and other findings characteristic for CLL, cell survival was analyzed in 20 B-CLL samples after 4 h of incubation with 1 mM bortezomib and compared to the percentage of leukemic cells, serum concentration of soluble CD23, the decrease in CD23-positive cells, and the mean fluorescence intensity (MFI) of CD23 expression. The relative sensitivity to PI was defined as the decrease in the percentage of viable cells after the in vitro treatment as compared to untreated samples. There was no obvious correlation between the relative sensitivity to PI and the percentage of CD5 þ CD19 þ CD23 þ triple-positive cells, or the serum concentration of soluble CD23 (not shown). However, the relative sensitivity to PI in vitro correlated significantly to the relative change in CD23 expression after 4 h of incubation (Figure 2a , also visible in Figure 1 ). Furthermore, a correlation was found between the relative sensitivity to PI and the mean fluorescence intensity of CD23 surface staining on nontreated cells (Figure 2b ).
PI antagonizes DNA binding of Notch2IC in B-CLL cells
Since CD23a is a target gene of Notch2 signaling and since nuclear extracts from freshly isolated B-CLL cells contain high amounts of activated Notch2IC, 5 we investigated whether the PI-mediated downregulation of CD23 is caused by a reduction in Notch2IC activity. EMSA were performed on nuclear extracts from B-CLL cells treated with PI (0.1-10 mM). To study the changes in Notch activity during the early stages of apoptosis and to minimize nonspecific degradation, nuclear extracts were prepared after 4 h of PI incubation when the majority of the cells were viable or in an early stage of apoptosis (see Figure 1 ). An oligonucleotide derived from the CD23a promoter spanning a well-defined CBF-1-binding site was used as a probe. 36 In accordance with our previous results, 5 EMSA visualized a Notch2IC containing transcription factor complex (C1) in the nontreated control (Figure 3a and b) . Incubation with PI MG132 (Figure 3a) or bortezomib (Figure 3b ) resulted in a dosedependent reduction of the DNA bound Notch2IC complex. Antibody inhibition assays using an anti-Notch2 antibody demonstrated the presence of Notch2IC in the C1 complexes (Figure 3a) . Since PI might also affect the g-secretase-mediated cleavage of membrane bound wT-Notch2 receptors, 37 B-CLL were treated with the potent g-secretase inhibitor compound E as a control. 38 As shown in Figure 3c , inhibition of g-secretase had no influence on the amount of DNA-bound Notch2IC complexes.
CD23a mRNA is downregulated in B-CLL cells during PI treatment
To demonstrate that the PI-mediated reduction of DNA-bound Notch2IC influences its transcriptional activity, B-CLL cells were analyzed for changes in gene expression of the Notch2 target gene CD23a after 4 h of PI incubation. The levels of CD23a, Notch2, and b-actin mRNA were measured by RT-PCR analysis. The amount of CD23a mRNA was clearly reduced after 4 h of PI incubation, whereas the levels of Notch2 mRNA changed moderately during this time period. An example of these studies is shown in the supplemental Figure 1. Time dependence of the effect of PI on CD23 expression and DNA-bound Notch2IC complexes
To get further insight into the regulation of Notch2 and CD23 during the apoptotic process, we analyzed Notch2 activity after 
Notch2 inactivation still occurs in the presence of caspase inhibitors
To support the proposition that inactivation of Notch2 takes place during the early phase of apoptosis rather than during the executive phase, caspase 3 was inhibited during the incubation of the CLL cells with PI. Incubating B-CLL cells (n ¼ 3) with 5 nM bortezomib alone for 24 h decreased the rate of viable cells by about 30% (Figure 5a 
Figure 4
The DNA-bound Notch2IC complex is lost either by short-term incubation with high PI concentrations or by incubation for 24 h with clinically relevant concentrations. Lymphocytes from CLL patients (n ¼ 3) were cultivated in the presence of bortezomib at the indicated concentrations for 4 h (left part) or for 24 h (right part). 
Transcription factor NF-AT is not affected by PI treatment
Since PI may affect many regulatory proteins in B-CLL cells, the effect of PI on NF-AT activity, another transcription factor which is constitutively active in B-CLL cells, 39 was investigated. As shown in supplemental Figure 2 , the NF-AT transcription factor complex was resistant to PI treatment, while the Notch2IC containing complex disappeared during the same observation period. This result might explain why the putative NF-AT target gene CD5 40 is not affected by PI.
Notch2 complex may modulate the response pattern of B-CLL cells to PI-induced apoptosis
Considerable differences were observed in B-CLL cells from different patients regarding the efficacy of apoptosis induction by PI. These different sensitivities were reflected by the amount of DNA-bound Notch2IC after 4 h of PI treatment. In Figure 6 , the Notch2 complexes of one CLL case with a rapid response rate to PI-induced apoptosis, and of one with a slower response are shown. In the highly sensitive cells, incubation for 4 h with 0.1 mM bortezomib resulted in complete loss of nuclear Notch2IC containing transcription factor complex and a decrease of cell viability and CD23 surface expression was observed. In contrast, only a slight reduction of the complex was seen in the less sensitive case even at a concentration of 10 mM, and cell viability and CD23 expression remained virtually unchanged after the 4 h incubation.
Notch2IC-transfected B-cell lines are relatively less sensitive to PI-mediated apoptosis
To investigate whether Notch2 directly modulates the sensitivity to PI-mediated apoptosis, a Notch2IC 'gain-of-function' phenotype was created in BL41 cells, a CD23 À human Burkitt's lymphoma cell line. Two retroviral vectors coding for the Cterminal, transcriptionally active portion of human Notch2 starting with the trans-membrane domain were constructed. In one construct, the protein destabilizing PEST region was deleted. BL41 was stably transduced with each vector giving rise to the BL41/N2IC and BL41/N2dP cells. Successful integration of the retroviral sequences into the genome was confirmed and induction of CD23 mRNA could be demonstrated (data not shown, manuscript in preparation). Compared to the nontransduced BL41 cells, both Notch2IC-transduced cell lines exhibited reduced sensitivity to PI to a similar extent ( Figure 7 ).
Discussion
A prominent feature of B-CLL cells is the high expression of CD23, which is closely related to cell survival 4 and Notch2 
Figure 7
Notch2-transfected BL41 cells exhibit higher resistance to PI-induced apoptosis. BL41, and stably transfected sublines expressing Notch2IC or Notch2ICDPEST were incubated with bortezomib at the indicated concentrations for 24 h. The number of viable cells was determined by Annexin V/propidium iodide staining and expressed relatively to the number of viable untreated cells. The mean values from three independent experiments are shown.
Proteasome inhibitors in B-CLL
M Duechler et al signaling. 5 Since several components of the Notch signaling cascade are tightly regulated by proteasomal degradation, we studied the effect of PI on Notch2 activity and CD23 expression.
It has been documented that B-CLL cells, upon in vitro treatment with proteasome inhibitors, undergo apoptosis. 29, 31, 41 This process has been shown to include conformational changes and mitochondrial translocation of Bax, 42 disruption of mitochondria, release of cytochrome c, and caspase activation. 43 In addition, PI may interfere with proteasomal degradation of apoptosis regulators such as the Bcl-2 family of proteins, p53, the IAPs and IkB, the inhibitor of nuclear factor-kappa B. 44 Although a proapoptotic function of PI in B-CLL cells through inhibition of NF-kB activity has been discussed, no alteration of nuclear NF-kB or cytoplasmic IkBa was observed after exposure to the proteasome inhibitor lactacystin. 35 Alternatively, nuclear accumulation of p53 has been considered as a possible mechanism, but a major role for the activity of p53 could not be confirmed. 45 Therefore, the molecular mechanisms leading to PI-mediated death of B-CLL cells in vitro are still not well understood.
In previous studies, we have shown that nuclear extracts from peripheral B-CLL cells contain active Notch2IC protein that is involved in the overexpression of CD23a. 5 Expression of CD23a has been implicated in cell survival in B-CLL cells, 4 and Notch proteins were shown to inhibit apoptosis in several models. [17] [18] [19] 46, 47 To investigate the effect of PI on Notch2 activity and CD23 expression, two compounds, bortezomib, which has already been employed in clinical trials for several malignancies, 33, 34, 48, 49 and MG-132 were tested. Bortezomib and MG-132 efficiently induced apoptosis in B-CLL cells in vitro and this process was accompanied by a decrease in the expression of CD23. Furthermore, as shown by EMSA to visualize the transcriptionally active protein, incubation of B-CLL cells with PI resulted in a strong reduction of Notch2IC complexes capable of binding to oligonucleotides derived from the CD23a promoter. One possible explanation for this effect could be the loss of binding capacity of ubiquitinated Notch2 to its transcription factor complex. This would be in agreement with the observation that ubiquitinated Notch1IC accumulates in the presence of MG132 and exhibits decreased promoter activity. 23 Another possible explanation is based on the observation that the PI also inhibit g-secretase activity, thereby preventing the generation of the Notch2IC fragment. 37 This possibility was ruled out by a series of experiments which show that blocking g-secretase activity with specific inhibitors 38 had no influence on the presence and the amount of the Notch2IC complex ( Figure 3c , and Hubmann et al, manuscript in preparation). The functional inactivation of Notch2IC as a transcriptional activator could be demonstrated by the downregulation of CD23a mRNA levels.
To prove that inactivation of Notch2 is not due to a nonspecific degradation in late apoptosis, but represents an early event in this process, several experiments were performed after 4 h of incubation, before the onset of cell death. The PIinduced reduction of the Notch2IC complex was already seen at this early time point, whereas NF-AT, another constitutively active transcription factor in B-CLL cells and its target gene CD5, remained unaffected. Blocking the execution phase of apoptosis by inhibition of caspase 3 did not prevent the disappearance of C1 complexes and downregulation of CD23, thus indicating that inactivation of Notch2IC takes place during the initiation phase rather than the execution phase of apoptosis.
In all CLL cases tested, a close association between the loss of DNA-bound Notch2IC complexes, downregulation of CD23, and an increase of the apoptotic rate was observed. This association became more evident when the sensitivity of B-CLL cells from different patients to PI was compared. The malignant lymphocytes from several patients responded rapidly to PI treatment and lost equally rapid CD23 surface expression and the Notch2IC transcription factor complex. The cells from other patients, however, were less sensitive and higher concentrations of PI were necessary to reduce the Notch2IC complexes after 4 h. Therefore, the persistence of the Notch2 complex seems to be related to the sensitivity of B-CLL cells to PI-induced apoptosis.
The transcriptional activity of Notch2 can be monitored by the expression of its target gene CD23. As a consequence, we found a significant correlation between the MFI of CD23 expression on freshly isolated CLL cells and the relative sensitivity of the cells to PI-induced apoptosis. In other words, it appears that a high Notch2 activity corresponds to a high density of CD23 on the cell surface and to a reduced sensitivity to PI-mediated apoptosis. Therefore, CD23 MFI seems to predict the sensitivity of B-CLL cells to PI. Further studies are necessary, however, to substantiate these findings.
To test the clinical relevance of these results, short-term incubations at a high dose of PI were compared to longer exposures with pharmacological doses of the compound. Treatment for 24 h with bortezomib in the nano-molar range resulted in a similar reduction of the Notch2 complex than short-time incubations with concentrations in the micromolar range. These data suggest that the Notch2 containing complex disappears as soon as the necessary concentration of PI is achieved. Similar responses may take place in other types of malignant cells.
To investigate whether enforced expression of a constitutively active form of Notch2IC is able to counteract cell death, 'gain of function' experiments were performed with the Burkitt's lymphoma cell line BL-41. Transduction of BL41 cells with Notch2IC reduced in fact the sensitivity of the cells to proteasome inhibition. These findings imply that Notch2 takes part in the regulation of apoptosis in B cells.
In conclusion, the data presented in this study indicate that PI-mediated apoptosis in B-CLL cells is associated with early inactivation of Notch2 and downregulation of its target gene CD23. The molecular mechanisms of a direct antiapoptotic role for these molecules in B-CLL remain to be clarified.
